Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.

Shi Y, Guryanova OA, Zhou W, Liu C, Huang Z, Fang X, Wang X, Chen C, Wu Q, He Z, Wang W, Zhang W, Jiang T, Liu Q, Chen Y, Wang W, Wu J, Kim L, Gimple RC, Feng H, Kung HF, Yu JS, Rich JN, Ping YF, Bian XW, Bao S.

Sci Transl Med. 2018 May 30;10(443). pii: eaah6816. doi: 10.1126/scitranslmed.aah6816.

2.

Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo.

Jeong M, Park HJ, Celik H, Ostrander EL, Reyes JM, Guzman A, Rodriguez B, Lei Y, Lee Y, Ding L, Guryanova OA, Li W, Goodell MA, Challen GA.

Cell Rep. 2018 Apr 3;23(1):1-10. doi: 10.1016/j.celrep.2018.03.025.

3.

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME.

Cancer Discov. 2017 Aug;7(8):868-883. doi: 10.1158/2159-8290.CD-16-1032. Epub 2017 Apr 13.

4.

FQI1: a transcription-methylation switch for cancer.

Guryanova OA, Licht JD.

Oncotarget. 2017 Feb 21;8(8):12536-12537. doi: 10.18632/oncotarget.15087. No abstract available.

5.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

6.

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.

Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL.

Leukemia. 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29.

7.

Defining ATM-Independent Functions of the Mre11 Complex with a Novel Mouse Model.

Balestrini A, Nicolas L, Yang-Lott K, Guryanova OA, Levine RL, Bassing CH, Chaudhuri J, Petrini JH.

Mol Cancer Res. 2016 Feb;14(2):185-95. doi: 10.1158/1541-7786.MCR-15-0281. Epub 2015 Nov 4.

8.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL.

Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

9.

A WIMSical approach to decoding DNA methylation in myeloid leukemia.

Guryanova OA, Levine RL.

Genome Biol. 2014;15(9):441. No abstract available.

10.

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL.

J Exp Med. 2013 Nov 18;210(12):2641-59. doi: 10.1084/jem.20131141. Epub 2013 Nov 11.

11.

Advances in the development of animal models of myeloid leukemias.

Guryanova OA, Levine RL.

Semin Hematol. 2013 Apr;50(2):145-55. doi: 10.1053/j.seminhematol.2013.03.027. Epub 2013 Jun 11. Review.

PMID:
24216171
12.

Cutaneous tumors cease CXCL9/Mig production as a result of IFN-γ-mediated immunoediting.

Petro M, Kish D, Guryanova OA, Ilyinskaya G, Kondratova A, Fairchild RL, Gorbachev AV.

J Immunol. 2013 Jan 15;190(2):832-41. doi: 10.4049/jimmunol.1201906. Epub 2012 Dec 12.

13.

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV.

Sci Transl Med. 2011 Aug 10;3(95):95ra74. doi: 10.1126/scitranslmed.3002530.

14.

Actin cytoskeleton remodeling by the alternatively spliced isoform of PDLIM4/RIL protein.

Guryanova OA, Drazba JA, Frolova EI, Chumakov PM.

J Biol Chem. 2011 Jul 29;286(30):26849-59. doi: 10.1074/jbc.M111.241554. Epub 2011 Jun 2.

15.

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S.

Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004.

16.

How scatter factor receptor c-MET contributes to tumor radioresistance: ready, set, scatter!

Guryanova OA, Bao S.

J Natl Cancer Inst. 2011 Apr 20;103(8):617-9. doi: 10.1093/jnci/djr103. Epub 2011 Apr 4. No abstract available.

PMID:
21464396
17.

Elevated invasive potential of glioblastoma stem cells.

Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN, Bao S.

Biochem Biophys Res Commun. 2011 Mar 25;406(4):643-8. doi: 10.1016/j.bbrc.2011.02.123. Epub 2011 Mar 1.

18.

L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.

Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S.

EMBO J. 2011 Mar 2;30(5):800-13. doi: 10.1038/emboj.2011.10. Epub 2011 Feb 4.

19.

Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells.

Huang Z, Wu Q, Guryanova OA, Cheng L, Shou W, Rich JN, Bao S.

Nat Cell Biol. 2011 Feb;13(2):142-52. doi: 10.1038/ncb2153. Epub 2011 Jan 23.

20.

Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.

Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S.

Protein Cell. 2010 Jul;1(7):638-55. doi: 10.1007/s13238-010-0078-y. Epub 2010 Jul 29. Review.

21.

Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors.

Gasparian AV, Guryanova OA, Chebotaev DV, Shishkin AA, Yemelyanov AY, Budunova IV.

Cell Cycle. 2009 May 15;8(10):1559-66. Epub 2009 May 13.

PMID:
19372735
22.

Optimization of a Genome-Wide Disordered Lentivector-Based Short Hairpin RNA Library.

Guryanova OA, Makhanov M, Chenchik AA, Chumakov PM, Frolova EI.

Mol Biol. 2006 May 1;40(3):396-405.

Supplemental Content

Loading ...
Support Center